Rovunaptabin is under clinical development by Berlin Cures and currently in Phase II for Post-Acute Sequelae of COVID 2019 (PASC or Long COVID). According to GlobalData, Phase II drugs for Post-Acute Sequelae of COVID 2019 (PASC or Long COVID) does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Rovunaptabin LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Rovunaptabin overview
Rovunaptabin is under development for the treatment of dilated cardiomyopathy with congestive heart failure, coronavirus disease 2019 (COVID-19) and glaucoma. The drug candidate is administered intravenously. The therapeutic candidate is a DNA aptamer which binds to beta1 adrenergic-receptor-autoantibodies. It is developed based on APTACURES platform of GPCR-AAB-binding-aptamers.
Berlin Cures overview
Berlin Cures is a biopharmaceutical company that focuses on the research and development of novel aptamer-based therapeutics. The company develops DNA-based aptamers to target and neutralize functional autoantibodies (fAABs) directed against G-protein coupled receptors (GPCRs). Its lead pipeline product includes BC 007 which targets heart failure, Long COVID and glaucoma. The company’s therapeutic areas also include sinus bradycardia. It operates in Switzerland and Germany. Berlin Cures is headquartered in Zug, Switzerland.
For a complete picture of Rovunaptabin’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
